You just read:

Censa Pharmaceuticals Announces CNSA-001 Met Primary and Secondary Endpoints in Phase 2 Trial in Patients with PKU

News provided by

Censa Pharmaceuticals, Inc.

Dec 03, 2019, 10:00 ET